Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 2 de 2
1.
Acta Paediatr ; 113(6): 1446-1452, 2024 Jun.
Article En | MEDLINE | ID: mdl-38329165

AIMS: The aim was to analyse the use and safety of bisphosphonate treatment for metabolic bone complications in paediatric cancer patients. METHODS: We retrospectively describe our experience with bisphosphonate treatment in 25 childhood cancer patients (aged <18 years) in a single tertiary hospital between 1999 and 2020. RESULTS: The most common primary diagnosis was acute lymphoblastic leukaemia (n = 16) and Hodgkin lymphoma (n = 3). Eleven patients (44%) had received allogeneic stem cell transplantation and two patients autologous stem cell transplantation. Sixteen patients (64%) had been treated with radiotherapy, either total-body (n = 11) or local (n = 5). The main indication for bisphosphonates was osteoporosis with vertebral compression fractures in 13/25, osteonecrosis in 6/25 and hypercalcaemia in 2/25. The bisphosphonate treatment was started on average 13 (range 0-76) months after the diagnosis of the bone complication. Bisphosphonate treatment lasted between weeks (hypercalcaemia) to 5 years (severe osteoporosis). Mild, non-symptomatic hypophosphatemia (n = 8), hypocalcaemia (n = 6) and moderate, transient pain (n = 6) were the most common adverse effects. No severe side effects were observed even when bisphosphonates were administered concomitantly with chemotherapy. Bone mineral density significantly improved with the bisphosphonate treatment (mean lumbar spine Z-score -1.17 vs. -0.07, p < 0.001). CONCLUSION: Bisphosphonate treatment was well tolerated in this paediatric patient cohort.


Bone Density Conservation Agents , Diphosphonates , Tertiary Care Centers , Humans , Female , Male , Child , Retrospective Studies , Diphosphonates/therapeutic use , Diphosphonates/adverse effects , Adolescent , Child, Preschool , Bone Density Conservation Agents/therapeutic use , Bone Density Conservation Agents/adverse effects , Neoplasms/complications , Osteoporosis/drug therapy , Bone Diseases, Metabolic/etiology , Bone Diseases, Metabolic/drug therapy , Infant
2.
Pediatr Transplant ; 14(2): 242-8, 2010 Mar.
Article En | MEDLINE | ID: mdl-19691523

Delayed immune reconstitution and the ensuing opportunistic infections among children following hematopoietic stem cell transplantation (HSCT) are associated with increased treatment-related morbidity and mortality (TRM). We retrospectively evaluated the impact of viral infections on the posttransplant recovery of pediatric recipients of stem cell grafts as a reflection of their posttransplant immunoreconstitution in a single institution setting. The case histories of 124 children (during 1/1999-9/2006) were reviewed for infectious episodes, and correlated with their respective clinical parameters. Patients with a high risk for CMV received prophylaxis, but failures in the prophylaxis were common (40%). 110/124 (89%) of these allogeneic patients had at least one viral reactivation/clinical infection posttransplant. In this group of pediatric patients chronic GVHD (P<0.001) and secondary graft failure were significantly (P=0.001) associated with early (during the first 100 days post HSCT), multiple (> or = 2) viral infections. Our data indicate that viruses are common pathogens among pediatric recipients of allogeneic stem cell grafts. In this group of patients multiple viral infections early on seem to reflect an even more severe degree of immunological derangement in the recipient and identify a group of patients with an increased risk of chronic GVHD and secondary graft failure.


Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Virus Diseases/etiology , Child , Chronic Disease , Female , Graft vs Host Disease/immunology , Hematopoietic Stem Cell Transplantation/mortality , Humans , Immunosuppressive Agents/adverse effects , Male , Retrospective Studies , Transplantation, Homologous/adverse effects , Virus Diseases/diagnosis
...